Anti-TNF Withdrawal in Inflammatory Bowel Disease

Detalhes bibliográficos
Autor(a) principal: Torres,Joana
Data de Publicação: 2016
Outros Autores: Cravo,Marília, Colombel,Jean-Frédéric
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452016000300006
Resumo: The introduction of the anti-tumor necrosis factorα agents (anti-TNFα) in clinical practice has greatly advanced the treatment of inflammatory bowel disease. The use of these medications results in durable remission in a subset of patients, preventing surgery and hospitalizations. However, there are some concerns about safety and costs associated with their long-term use. Therefore, anti-TNF withdrawal has emerged as an important consideration in clinical practice. Herein our goal was to discuss the available evidence about anti-TNFα discontinuation in IBD that could inform the clinician on the expected rates of relapse, the potential predictors of relapse, as well the response to re-treatment.
id RCAP_20cd005708b43e6720e27e6e68eb9d9a
oai_identifier_str oai:scielo:S2341-45452016000300006
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Anti-TNF Withdrawal in Inflammatory Bowel DiseaseInflammatory Bowel Diseases/drug therapyTumor Necrosis Factor-Alpha/antagonists and inhibitorsTumor Necrosis Factor-Alpha/therapeutic useWithholding TreatmentThe introduction of the anti-tumor necrosis factorα agents (anti-TNFα) in clinical practice has greatly advanced the treatment of inflammatory bowel disease. The use of these medications results in durable remission in a subset of patients, preventing surgery and hospitalizations. However, there are some concerns about safety and costs associated with their long-term use. Therefore, anti-TNF withdrawal has emerged as an important consideration in clinical practice. Herein our goal was to discuss the available evidence about anti-TNFα discontinuation in IBD that could inform the clinician on the expected rates of relapse, the potential predictors of relapse, as well the response to re-treatment.Sociedade Portuguesa de Gastrenterologia2016-06-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articletext/htmlhttp://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452016000300006GE-Portuguese Journal of Gastroenterology v.23 n.3 2016reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPenghttp://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452016000300006Torres,JoanaCravo,MaríliaColombel,Jean-Frédéricinfo:eu-repo/semantics/openAccess2024-02-06T17:33:40Zoai:scielo:S2341-45452016000300006Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T02:35:57.177110Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Anti-TNF Withdrawal in Inflammatory Bowel Disease
title Anti-TNF Withdrawal in Inflammatory Bowel Disease
spellingShingle Anti-TNF Withdrawal in Inflammatory Bowel Disease
Torres,Joana
Inflammatory Bowel Diseases/drug therapy
Tumor Necrosis Factor-Alpha/antagonists and inhibitors
Tumor Necrosis Factor-Alpha/therapeutic use
Withholding Treatment
title_short Anti-TNF Withdrawal in Inflammatory Bowel Disease
title_full Anti-TNF Withdrawal in Inflammatory Bowel Disease
title_fullStr Anti-TNF Withdrawal in Inflammatory Bowel Disease
title_full_unstemmed Anti-TNF Withdrawal in Inflammatory Bowel Disease
title_sort Anti-TNF Withdrawal in Inflammatory Bowel Disease
author Torres,Joana
author_facet Torres,Joana
Cravo,Marília
Colombel,Jean-Frédéric
author_role author
author2 Cravo,Marília
Colombel,Jean-Frédéric
author2_role author
author
dc.contributor.author.fl_str_mv Torres,Joana
Cravo,Marília
Colombel,Jean-Frédéric
dc.subject.por.fl_str_mv Inflammatory Bowel Diseases/drug therapy
Tumor Necrosis Factor-Alpha/antagonists and inhibitors
Tumor Necrosis Factor-Alpha/therapeutic use
Withholding Treatment
topic Inflammatory Bowel Diseases/drug therapy
Tumor Necrosis Factor-Alpha/antagonists and inhibitors
Tumor Necrosis Factor-Alpha/therapeutic use
Withholding Treatment
description The introduction of the anti-tumor necrosis factorα agents (anti-TNFα) in clinical practice has greatly advanced the treatment of inflammatory bowel disease. The use of these medications results in durable remission in a subset of patients, preventing surgery and hospitalizations. However, there are some concerns about safety and costs associated with their long-term use. Therefore, anti-TNF withdrawal has emerged as an important consideration in clinical practice. Herein our goal was to discuss the available evidence about anti-TNFα discontinuation in IBD that could inform the clinician on the expected rates of relapse, the potential predictors of relapse, as well the response to re-treatment.
publishDate 2016
dc.date.none.fl_str_mv 2016-06-01
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452016000300006
url http://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452016000300006
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv http://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452016000300006
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Portuguesa de Gastrenterologia
publisher.none.fl_str_mv Sociedade Portuguesa de Gastrenterologia
dc.source.none.fl_str_mv GE-Portuguese Journal of Gastroenterology v.23 n.3 2016
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1817552599767842816

Registros relacionados